Fig. 2

Clinical relevance of miR-199b-5p across AML subtypes. a Kaplan–Meier analysis of 166 AML patients from the TCGA database for high/low miR-199b expression and overall survival, p = 0.0164. b miR-199b cytogenetic risk for same patients set. c High/low miR-199b expression by FAB subtype in the same patients set. d Least squared means plot of 199b expression for different FAB subtypes using ANOVA (p < 0.0001). e miR-199b levels for n = 128 AML patients analyzed for miR-199b/NPM1 with n = 63 miR-199b-high samples, of which n = 2 were positive for NPM1 mutation, and n = 65 miR-199b-low samples of which n = 41 positive for NPM1 mutation (Fisher p value = 1.941e-08, odds ratio 19.6112) (left panel). miR-199b levels for n = 139 patients with n = 59 miR-199b-high samples (of which n = 5 positive for IDH1 mutation) whereas n = 80 were miR-199b-low samples with n = 25 positive for IDH1 mutation (Fisher p value = 0.01175, odds ratio 3.663005) (right panel)